REGENXBIO Inc. 8-K

What Happened
REGENXBIO Inc. announced on June 29, 2026 (Form 8-K) that it has earned a $100.0 million milestone payment from AbbVie Global Enterprises Ltd. The payment arises under the Collaboration and License Agreement (originally dated September 10, 2021; amended August 5, 2025) and relates to dosing the first patient in the Phase IIb/III trial of surabgene lomparvovec (sura-vec, ABBV‑RGX‑314) for diabetic retinopathy using suprachoroidal delivery. The company expects to receive the payment in July 2026.

Key Details

• Amount: $100.0 million milestone payment.
• Trigger: Dosing of the first patient in AbbVie’s Phase IIb/III trial of surabgene lomparvovec in diabetic retinopathy.
• Agreement: Under the Collaboration and License Agreement between REGENXBIO and AbbVie (Sep 10, 2021; amended Aug 5, 2025).
• Timing: Announcement filed June 29, 2026; payment expected in July 2026.

Why It Matters
This is a material, non-operational cash milestone tied to progress in a partnered clinical program. For investors, the payment represents near-term cash inflow and confirms AbbVie advanced the clinical trial to its first dosing milestone under the collaboration. The filing is an update under Item 8.01 (Other Events) and signals a concrete development in REGENXBIO’s partnered pipeline.